LivaNova PLC (NASDAQ:LIVN) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, November 2nd.
LIVN has been the topic of a number of other reports. Jefferies Group LLC assumed coverage on shares of LivaNova PLC in a research note on Friday, September 8th. They set a “buy” rating and a $76.00 price target on the stock. Needham & Company LLC raised shares of LivaNova PLC from a “hold” rating to a “buy” rating and set a $83.00 price target on the stock in a research note on Friday, September 15th. Piper Jaffray Companies reissued an “overweight” rating and set a $75.00 price target on shares of LivaNova PLC in a research note on Tuesday, September 12th. BidaskClub downgraded shares of LivaNova PLC from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Finally, WBB Securities downgraded shares of LivaNova PLC from a “hold” rating to a “sell” rating and set a $50.00 price target on the stock. in a research note on Tuesday, August 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $79.14.
LivaNova PLC (NASDAQ:LIVN) opened at $85.78 on Thursday. The company has a current ratio of 2.03, a quick ratio of 1.42 and a debt-to-equity ratio of 0.04. The firm has a market cap of $4,068.09, a PE ratio of 24.32, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. LivaNova PLC has a 1 year low of $42.97 and a 1 year high of $85.84.
LivaNova PLC (NASDAQ:LIVN) last released its quarterly earnings data on Thursday, November 2nd. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.76 by $0.17. The company had revenue of $309.70 million during the quarter, compared to analyst estimates of $301.22 million. LivaNova PLC had a net margin of 4.63% and a return on equity of 9.33%. LivaNova PLC’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the business earned $0.78 earnings per share. sell-side analysts expect that LivaNova PLC will post 3.33 EPS for the current fiscal year.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the business’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $68.55, for a total transaction of $68,550.00. Following the sale, the director now owns 57,296 shares in the company, valued at approximately $3,927,640.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 3,000 shares of company stock worth $224,520. Company insiders own 0.28% of the company’s stock.
A number of large investors have recently modified their holdings of LIVN. PNC Financial Services Group Inc. raised its position in LivaNova PLC by 9.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock worth $105,000 after buying an additional 153 shares during the last quarter. Riverhead Capital Management LLC raised its position in LivaNova PLC by 76.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock worth $108,000 after buying an additional 763 shares during the last quarter. Exane Derivatives raised its position in LivaNova PLC by 814.8% in the 2nd quarter. Exane Derivatives now owns 3,156 shares of the company’s stock worth $158,000 after buying an additional 2,811 shares during the last quarter. Teacher Retirement System of Texas purchased a new position in LivaNova PLC in the 2nd quarter worth about $204,000. Finally, LS Investment Advisors LLC raised its position in LivaNova PLC by 14.5% in the 2nd quarter. LS Investment Advisors LLC now owns 3,449 shares of the company’s stock worth $211,000 after buying an additional 436 shares during the last quarter. 81.82% of the stock is owned by institutional investors and hedge funds.
About LivaNova PLC
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with our FREE daily email newsletter.